申请人:Cassella Farbwerke Mainkur Aktiengesellschaft
公开号:US04216314A1
公开(公告)日:1980-08-05
Physiologically-acceptable substituted 1,2-ethylenediamines and 1,3-propylenediamines, in free-base and in acid-addition-salt form, have highly pronounced and cardioselective .beta.-adrenolytic action, antiarrhythmic action and hypotensive action on administration to humans. The diamines are, more specifically, N-[3-aryloxy-2-hydroxypropyl]-N'-[1,3-(di-R.sup.3)-2,4-dioxypyrimid-6-yl] (ethylene or propylene)diamines wherein R.sup.3 is --H or lower alkyl and the aryl nucleus is either further unsubstituted, further monosubstituted or further disubstituted. The compounds are prepared, e.g, by reacting a corresponding N-[3-phenoxy-2-hydroxypropyl] (ethylene or propylene)diamine with a corresponding 6-chloropyrimidine-2,4-dione in a suitable medium containing an acid-binding agent. Such compounds are administered orally or parenterally in effective, but substantially non-toxic, doses either in substantially pure form, in virtually any standard dosage form or in combination with one or more other pharmacologically- and chemically-compatible drugs.
生理上可接受的取代的1,2-乙二胺和1,3-丙二胺,以游离基和酸加成盐的形式,在人体内具有高度显著和心脏选择性的β-肾上腺素受体阻滞作用,抗心律失常作用和降压作用。这些二胺具体来说是N-[3-芳氧基-2-羟基丙基]-N'-[1,3-(二-R.sup.3)-2,4-二氧嘧啶-6-基](乙烯或丙烯)二胺,其中R.sup.3为--H或低碳基,芳香核可以进一步未取代,单取代或双取代。这些化合物可以通过将相应的N-[3-苯氧基-2-羟基丙基](乙烯或丙烯)二胺与相应的6-氯嘧啶-2,4-二酮在含有酸中和剂的适当介质中反应制备而成。这些化合物可以以有效但基本无毒的剂量口服或静脉注射,可以是基本纯的形式,也可以是几乎任何标准剂型的形式或与一个或多个其他药理学和化学兼容的药物联合使用。